�Cortex Pharmaceuticals, Inc. (AMEX:
COR - News) reported that top-line data from its first Phase IIa
study in opiate-induced respiratory depression (RD) demonstrated that
a single oral venereal disease of 2100mg of AMPAKINE� CX717 achieved statistical
significance over placebo on the primary end point measure. These
results ar being presented at the Bank of Montreal Capital Markets
Focus on Healthcare Conference in New York City on Wednesday roved for the treatment of any disease. Cortex
disclaims whatever intent or obligation to update whatever forward-looking
statements.
Cortex Pharmaceuticals, Inc.
More information
